Skip to main content
SpringerLink
Log in

Quality Control of Cellular Therapy Products and Viral Vectors

  • Chapter
  • First Online:
Cell Therapy

Abstract

Quality control of cellular therapy products is an essential component of determining their safety and efficacy. This chapter reviews the various components of quality control testing of both cellular therapy products and viral vectors.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Dictionary.com website. (2020). www.dictionary.com. Last accessed 3 Aug 2020.

  2. U.S. Food and Drug Administration. (2006, September). Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER) Guidance for Industry. Quality Systems Approach to Pharmaceutical CGMP Regulations. https://www.fda.gov/media/71023/download. Last accessed 3 Aug 2020.

  3. U.S. Food and Drug Administration. (2008, April ). Center for Biologics Evaluation and Research. Guidance for FDA Reviewers and Sponsors: Content and Review of Chemistry, Manufacturing, and Control (CMC) Information for Human Somatic Cell Therapy Investigational New Drug Applications (INDs). https://www.fda.gov/media/73624/download. Last accessed 3 Aug 2020.

  4. U.S. Food and Drug Administration. (2020, January ). Center for Biologics Evaluation and Research. Guidance for Industry: Chemistry, Manufacturing, and Control (CMC) Information for Human Gene Therapy Investigational New Drug Applications (INDs). https://www.fda.gov/media/113760/download. Last accessed 3 Aug 2020.

  5. U.S. Food and Drug Administration. Sterility. Code of Federal regulations Title 21 Part 610.12. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=610.1. Last accessed 3 Aug 2020.

  6. Sterility Tests. United States Pharmacopoeia <71>. http://www.triphasepharmasolutions.com/Private/USP%2071%20STERILITY%20TESTS.pdf. Last accessed 3 Aug 2020.

  7. BD BACTECâ„¢ FX Blood Culture System. https://www.bd.com/en-us/offerings/capabilities/microbiology-solutions/blood-culture/blood-culture-instrumentation/bd-bactec-fx-blood-culture-system. Last accessed 3 Aug 2020.

  8. BACT/ALERT® 3D. https://www.biomerieux-usa.com/bactalert3d/automatedsystem. Last accessed 3 Aug 2020.

  9. Center for Biologics Evaluation and Research. (2008, February). Testing of cellular and gene therapy products. Food and drug administration. http://rapidmicromethods.com/references/Validation%20of%20Growth-Based%20Rapid%20Microbiological%20Methods%20for%20Sterility%20Testing%202011.pdf. Last accessed 3 Aug 2020.

  10. England, M. R., Stock, F., Gebo, J. E. T., Frank, K. M., et al. (2019). Comprehensive evaluation of compendial USP<71>, BacT/Alert dual-T, and Bactec FX for detection of product sterility testing contaminants. Journal of Clinical Microbiology, 57(2), e01548-18. https://jcm.asm.org/content/jcm/57/2/e01548-18.full.pdf. Last accessed 3 Aug 2020

    Article  Google Scholar 

  11. Khuu, H. M., Stock, F., McGann, M., et al. (2004) Comparison of automated culture systems with a CFR/USP-compliant method for sterility testing of cell-therapy products. Cytotherapy, 6, 183–195.

    Google Scholar 

  12. Code of Federal regulations Mycoplasma Subpart D. Title 21 Part 610.30. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=610.30. Last accessed 3 Aug 2020.

  13. ThermoFisher Scientific website. MycoSEQâ„¢ Mycoplasma Detection Kit. https://www.thermofisher.com/order/catalog/product/4460623#/4460623. Last accessed 3 Aug 2020.

  14. Roche website. MycoTOOL Mycoplasma Real-Time PCR Kit. https://custombiotech.roche.com/home/Product_Details/3_5_3_19_3_2.product-classes%5CTestKits.html. Last accessed 3 Aug 2020.

  15. Lonza website. MycoAlertâ„¢ Mycoplasma Detection Kits, Lonza. https://us.vwr.com/store/product/21346689/mycoalerttm-mycoplasma-detection-kits-lonza. Last accessed 3 Aug 2020.

  16. bioMérieux website. (2020). Launch of BIOFIRE® MYCOPLASMA test for mycoplasma detection in biopharmaceutical products. https://www.biomerieux.com/en/launch-biofirer-mycoplasma-test-mycoplasma-detection-biopharmaceutical-products. Last accessed 3 Aug 2020.

  17. Russell, C. M., Brenton, M., LaBombard, S., Schieving, A., et al. (2014). Regulatory aspects of mycoplasma testing for cell therapy products. http://www.stem-art.com/Library/Miscellaneous/Regulatory%20Aspects%20of%20Mycoplasma%20Testing%20for%20Cell%20Therapy%20Products.pdf. Last accessed 3 Aug 2020.

  18. Economics Staff, Office of Planning. (2019). Elimination of 21 CFR 610.30 Test for Mycoplasma. Docket No. FDA-2018-N-4757. https://www.fda.gov/media/122863/download. Last accessed 3 Aug 2020.

  19. Draft of Points to Consider in the Characterization of Cell Lines Used to Produce Biologicals. (1993). https://www.fda.gov/media/76255/download. Last accessed 3 Aug 2020.

  20. European Medicines Agency website. ICH Q5A (R1) Quality of biotechnological products: viral safety evaluation of biotechnology products derived from cell lines of human or animal origin. https://www.ema.europa.eu/en/ich-q5a-r1-quality-biotechnological-products-viral-safety-evaluation-biotechnology-products-derived. Last accessed 3 Aug 2020.

  21. U.S. Food and Drug Administration. Subpart C – donor eligibility. Title 21 Code of Federal Regulations Part 1271. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=1271&showFR=1&subpartNode=21:8.0.1.5.60.3. Last accessed 3 Aug 2020.

  22. U.S. Food and Drug Administration. 610.13 Purity. Title 21 Code of Federal Regulations Part 610 General Biological Product Standards. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=610.13. Last accessed 3 Aug 2020.

  23. U.S Food and Drug Administration. (2012). Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER) Center for Veterinary Medicine (CVM) Center for Devices and Radiological Health (CDRH) Pyrogen and Endotoxins Testing: Questions and Answers. Guidance for industry. https://www.fda.gov/media/83477/download. Last accessed 3 Aug 2020.

  24. Charles River website. Endosafe® nexgen-PTS™. https://www.criver.com/products-services/qc-microbial-solutions/endotoxin-testing/endotoxin-testing-systems/endosafe-nexgen-pts?region=3611. Last accessed 3 Aug 2020.

  25. Strober, W. (2015, November 2). Trypan blue exclusion test of cell viability. Current Protocols in Immunology, 111, A3.B.1–A3.B.3. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6716531/. Last accessed 3 Aug 2020.

  26. R&D Systems website. 7-amino actinomycin D (7-AAD) cell viability flow cytometry protocol. https://www.rndsystems.com/resources/protocols/analysis-cell-viability-using-7-amino-actinomycin-d-7-aad. Last accessed 3 Aug 2020.

  27. Lakshmanan, I., & Batra, S. K. (2013, March 20). Protocol for apoptosis assay by flow cytometry using Annexin V staining method. Bio-Protocol, 3(6), e374. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4943750/. Last accessed 3 Aug 2020.

  28. Nexelom website. Automated cell counters, image cytometers and reagents. https://www.nexcelom.com/nexcelom-products/?gclid=EAIaIQobChMIuabU99fw6gIVzsDACh1skAp9EAAYASAAEgJBFvD_BwE. Last accessed 3 Aug 2020.

  29. Chemometec website. NucleoCounter® NC-202™ automated cell counter. https://chemometec.com/cell-counters/nc-202-automated-cell-counter/. Last accessed 3 Aug 2020.

  30. European Medicines Agency website. ICH Topic Q 1 E evaluation of stability data. https://www.ema.europa.eu/en/documents/scientific-guideline/ich-q-1-e-evaluation-stability-data-step-5_en.pdf. Last accessed 3 Aug 2020.

  31. ICH Harmonized Tripartite Guideline. (2003). Stability testing of new drug substances and products Q1A (R2). http://academy.gmp-compliance.org/guidemgr/files/Q1A(R2)%20Step4%20(2).pdf. Last accessed 3 Aug 2020.

  32. Yang, H. (2013). Establishing acceptable limits of residual DNA. PDA Journal of Pharmaceutical Science and Technology, 67(2), 155–163.

    Article  CAS  Google Scholar 

  33. U.S. Pharmacopeia. Residual host cell protein measurement in biopharmaceuticals. USP <1132>. https://www.usp.org/sites/default/files/usp/document/our-work/biologics/USPNF810G-GC-1132-2017-01.pdf. Last accessed 3 Aug 2020.

  34. U.S. Food and Drug Administration. (2016, September). Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER) Q7 Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients. Guidance for Industry. https://www.fda.gov/media/71518/download. Last accessed 3 Aug 2020.

  35. Parry, D. (2012). Duties of key personnel in GMP – Part 1 (production, QC and the QP). Inspired Pharma Training website. https://www.inspiredpharma.com/2012/04/03/duties-of-key-personnel-in-gmp-part-1-production-qc-and-the-qp/. Last accessed 3 Aug 2020.

Download references

Acknowledgments

This work was supported in part by a Core grant (RP180785) from the Cancer Research and Prevention Institute of Texas.

I would like to thank Sara Richman of the Center for Cell and Gene Therapy for reviewing this chapter.

Author information

Authors and Affiliations

  1. Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX, USA

    Adrian P. Gee

Authors
  1. Adrian P. Gee
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Adrian P. Gee .

Editor information

Editors and Affiliations

  1. Texas Children’s Cancer Center, Center for Cell and Gene Therapy, Houston, TX, USA

    Adrian P. Gee

Rights and permissions

Reprints and permissions

Copyright information

© 2022 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Gee, A.P. (2022). Quality Control of Cellular Therapy Products and Viral Vectors. In: Gee, A.P. (eds) Cell Therapy. Springer, Cham. https://doi.org/10.1007/978-3-030-75537-9_12

Download citation

Publish with us

Policies and ethics

Search

Navigation